Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo

Bioscience, Biotechnology and Biochemistry

Volumn 71, Issue 1, 2007, Pages 215-221

  Kim, Gi Young ^a   Chae, Ho Jin ^a   Kim, Ki Hyung ^b   Yoon, Man Soo ^b   Lee, Kyu Sub ^b   Lee, Chang Min ^b   Moon, Dong Oh ^a   Lee, Jun Sik ^b   Jeong, Young Il ^b   Yung, Hyun Choi ^c   Park, Yeong Min ^b  

^a Jeju National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Dong Eui University   (South Korea)

Author keywords

(IFN ); Dendritic cells; IL 12; Interferon ; MCA 102 fibrosarcoma; Tumor lysate

Indexed keywords

DISEASE CONTROL; GROWTH KINETICS; TUMORS; VACCINES;

DENDRITIC CELLS; INTERFERON; MCA-102 FIBROSARCOMA; TUMOR LYSATE;

CELLS;

CANCER VACCINE;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CELL FUSION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; HUMAN; IMMUNOLOGY; MOUSE; NEOPLASM; PATHOLOGY; PHENOTYPE;

ANIMALS; CANCER VACCINES; CELL FUSION; CELLS, CULTURED; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; MURINAE;

EID: 33846495008     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.60517     Document Type: Article

References (19)

1. Crowley, M., Inaba, K., and Steinman, R. M., Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins. J. Exp. Med., 172, 383-386 (1990).
2. Steinman, R. M., The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol., 9, 271-296 (1991).
3. Banchereau, J., and Steinman, R. M., Dendritic cells and the control of immunity. Nature, 392, 245-252 (1998).
4. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B., and Palucka, K., Immunobiology of dendritic cells. Annu. Rev. Immunol., 18, 767-811 (2000).
5. Celluzzi, C. M., and Falo, L. D. Jr., Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol., 160, 3081-3085 (1998).
6. Miconnet, I., Coste, I., Beermann, F., Haeuw, J. F., Cerottini, J. C., Bonnefoy, J. Y., Romero, P., and Renno, T., Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. J. Immunol., 166, 4612-4619 (2001).
7. Wang, H. Y., Fu, T., Wang, G., Zeng, G., Perry-Lalley, D. M., Yang, J. C., Restifo, N. P., Hwu, P., and Wang, R. F., Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J. Clin. Invest., 109, 1463-1470 (2002).
8. Fields, R. C., Shimizu, K., and Mule, J. J., Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 95, 9482-9487 (1998).
9. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4, 328-332 (1998).
10. Nishioka, Y., Hirao, M., Robbins, P. D., Lotze, M. T., and Tahara, H., Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin-12. Cancer Res., 59, 4035-4041 (1999).
11. Rodriquez-Calvillo, M., Duarte, M., Tirapu, I., Berraondo, P., Mazzolini, G., Qian, C., Prieto, J., and Melero, I., Upregulation of natural killer cell functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Exp. Hematol., 30, 195-204 (2002).
12. Gong, J., Nikrui, N., Chen, D., Koido, S., Wu, Z., Tanaka, Y., Cannistra, S., Avigan, D., and Kufe, D., Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol., 3, 558-561 (1997).
13. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., and Falo, L. D. Jr., Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med., 183, 283-287 (1996).
14. Gong, J., Avigan, D., Chen, D., Wu, Z., Koido, S., Kashiwaba, M., and Kufe, D., Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA, 97, 2715-2718 (1998).
15. Lespagnard, L., Mettens, P., Verheyden, A. M., Tasiaux, N., Thielemans, K., van Meirvenne, S., Geldhof, A., Baetselier, P., Urbain, J., Leo, O., and Moser, M., Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Int. J. Cancer, 76, 250-258 (1998).
16. Crowley, M., Inaba, K., and Steinman, R. M., Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins. J. Exp. Med., 172, 383-386 (1990).
17. Kodaira, Y., Ikuta, K., Tanaka, S., and Yolomuro, K., Antigen-driven clonal accumulation of peritoneal gammadelta T cells in vivo. Immunol. Invest., 28, 137-148 (1999).
18. Avigan, D., Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin. Cancer Res., 10, 6347-6352 (2004).
19. Kikuchi, T., Akasaki, Y., Irie, M., Homma, S., Abe, T., and Ohno, T., Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother., 50, 337-344 (2001).